

PHILIPS

www.philips.com

Philips V60 Plus Philips AC611

Hospital Respiratory Care
September 2018

innovation  you



Objectives

- Review the evidence-based approaches for the treatment of acute respiratory failure
- Introduce Philips V60 Plus & AC611 high flow nasal cannula (HFNC)
- Clinical dilemmas
- Smooth transition NIV – HFT – NIV
- How V60 Plus and AC611 fits in your treatment strategies

Review of evidence-based approaches for the treatment of ARF

Executive summary of the current landscape

Noninvasive clinical scenario	NIV	HFNC
COPD exacerbation (pH 7.25–7.35)	Highly recommended	No data
Community-acquired pneumonia	Recommended	Recommended
Immunocompromised patients	Recommended	Recommended
Hypoxemic respiratory failure		
PaO ₂ /FiO ₂ 200–300	Recommended	Recommended
PaO ₂ /FiO ₂ < 200	High risk	Recommended
Cardiogenic pulmonary edema	Highly recommended	No data
Post-extubation for high-risk patients (immediately post)	Recommended	Recommended
Post-extubation with COPD (early liberation)	Recommended	No data
Postoperative patients	Recommended	Inferior

Highly recommended

Recommended

Mixed evidence

Inferior

No data

High risk

Recommendation based on the author's review of the currently available literature, including existing guidelines.

* Mixed evidence exists in this category, without a clear consensus in the literature. Monitor patients closely and consider the presence of other risk factors.

Review of evidence-based approaches for the treatment of ARF

Executive summary of the current landscape

Noninvasive clinical scenario

	NIV	HFNC
COPD exacerbation (pH 7.25–7.35)	Highly recommended	No data
Community-acquired pneumonia	Mixed evidence *	Recommended
Immunocompromised patients	Recommended	Recommended
Hypoxemic respiratory failure		
PaO ₂ /FiO ₂ 200–300	Recommended	Recommended
PaO ₂ /FiO ₂ < 200	High risk	Recommended
Cardiogenic pulmonary edema	Highly recommended	No data
Post-extubation for high-risk patients (immediately post)	Recommended	Recommended
Post-extubation with COPD (early liberation)	Recommended	No data
Postoperative patients	Recommended	Inferior

Highly recommended

Recommended

Mixed evidence

Inferior

No data

High risk

Recommendation based on the author's review of the currently available literature, including existing guidelines.

* Mixed evidence exists in this category, without a clear consensus in the literature. Monitor patients closely and consider the presence of other risk factors.

NIV



- COPD Exacerbation hypercapnic respiratory failure
 - Cardiogenic Pulmonary Edema
 - Weaning
 - Immunosuppressed
 - At risk COPD, post-extubation
 - Chest trauma, palliative care, post-op
- *Enhances ventilation (tidal volume) and oxygenation (alveolar recruitment)

HFT



- COPD exacerbation -hypoxemic respiratory failure
- Pneumonia, Mild ARDS
 - De novo hypoxemic respiratory failure

*Flush deadspace, provides positive end expiratory pressure
*Meet or exceed patient's inspiratory flow demand while delivering the prescribed FiO₂

What is high flow therapy?

Meets or exceeds inspiratory flow demand

Requires heating and humidification

Delivers a wide range of FiO_2

Provides a small PEEP effect

Washes out CO_2 from anatomical deadspace



What we know

68%

Clinicians report using NIV & HFT on the same ARF patient.¹

87%


NIPPV prevented intubation in a recent non-inferiority study of patients who failed HFT.²

1. Quantitative market research. Report of Findings: High flow Nasal Cannula Oxygen Therapy Research – US & Europe. Junicon, December 31, 2014
2. Doshi, Pratik et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Emergency Medicine Journal 2018. DOI: <https://doi.org/10.1016/j.annemergmed.2017.12.006>.



Need to escalate care

- At initial presentation of the acute respiratory failure patient, the full clinical picture has yet to be painted.
- Provide the least invasive approach to achieve treatment success with patient comfort in mind.
- Rapid care escalation to NIV is critical to success, when HFT does not provide desired effect.
- Improved workflow improves quality of bedside care
- Fleet management and consumable redundancies are costly



V60 Plus and AC611

A comprehensive noninvasive solution

“It is convenient for the patient and staff. Most patients are on/off HFT and BiPAP. It saves time, space and the patient gets the appropriate treatment faster.” RCP


The synergistic combination of NIV and HFT in the V60 Plus will enable quick, smooth transitions within the noninvasive respiratory care continuum while improving clinician workflow and streamlining equipment & consumables.

- Facilitates rapid switching between NIV and HFT
- Designed for efficient patient weaning
- Enables quick escalation and intervention for optimal patient care
- Allows more space at the bedside for timely patient care



V60 Plus and AC611

A comprehensive noninvasive respiratory solution



V60

HFT



V60 Plus
with the AC611 HFNC

V60 Plus and the AC611

Clinicians will benefit

- Saving time
- Increased work space
- One gas source
- Improved workflow
- Use of the same circuit



V60 Plus and the AC611

Patients will benefit

- Efficient workflow
- Receive enhanced care experience
- Peace of mind
- Interface rotation to meet skin care strategy



Clinical dilemma

Time to escalation is critical



Escalate



Easily and quickly switch between NIV → HFT → NIV

- A break from NIV to speak to family members, to eat, to take a drink
- Removing therapy may lead to desaturation
- No need to leave the patient bedside with the V60 Plus and the AC611
- Smooth transition NIV → HFT → NIV



Wean from NIV to HFT



Wean



Overview of V60 Plus



Intended for spontaneous breathing patients

Use with Heated Humidification

Philips AC611

Flow rates 10-80 Lpm


O2 concentration 21-100%


Adults & pediatrics >20 kg

V60 Plus and AC611- NIV to HFT

Transition from NIV to HFT


- Select Standby tab
- Remove the NIV mask or ET interface to enter Standby






Transition from NIV to HFT

- Insert The Philips AC611 to block the FEP of your single limb NIV circuit
- Fisher & Paykel OPT970 is the Philips approved tracheostomy interface for the V60 Plus



Transition from NIV to HFT

Philips AC611



Use insertion
sleeve to
block FEP

Philips AC611
FEP Connect




Exhalation
Port (DEP)
is removed

Philips AC611
22 mm adaptor

Transition from NIV to HFT

Confirm settings
Flow 10-80 Lpm
O2 21-100%

Flow

10  80

< **65** >
L/min


✓ Accept
✗ Cancel

Active Mode: HFT

Flow L/min 60 O2 % 35

HFT Settings Modes Menu Standby ?

Oxygen

21  100

< **40** >
%

✓ Accept
✗ Cancel


Active Mode: HFT

Flow L/min 65 O2 % 35

HFT Settings Modes Menu Standby ?

Start HFT

Standby - Not Delivering Therapy

 NO MASK

Start HFT


Do not use NIV masks in HFT

Active Mode: HFT

Flow L/min 60 O2 % 35

HFT Settings Modes ?

Transition from NIV to HFT




*Use the F&P OPT 970 adaptor when providing HFT to a tracheostomy patient.

V60 Plus high flow therapy notifications and alarms

V60 Plus HFT notification and alarms


No Mask icon



High Flow Therapy Active

Low Priority Alarm to alert the clinician that Patient alarms are disabled during HFT.

V60 Plus HFT notification and alarms




Low Priority Alarm to alert the clinician that Patient alarms are disabled during HFT.

Note the *Alarm Tab* is removed


*Clinicians must rely on patient assessment skill and external monitoring to evaluate their response to therapy.

V60 Plus HFT notification and alarms



Cannot Reach Target Flow

This low priority alarm displays when indicating that set flow target is not being achieved.



Patient Circuit Occluded

This high priority alarm displays when gas flow to the patient is obstructed.

Confirm:



- The interface in use is **NOT** an NIV mask or direct connection to an ET-tube or trach.
- Size of nasal cannula is appropriate for the flow setting.
- The interface is **NOT** occluding inside the nares.
- Patient circuit is not kinked or occluded.

V60 Plus and AC611- HFT to NIV

V60 Plus and AC611 – HFT to NIV

When transitioning from HFT to NIV, first verify that the AC611 is removed from the patient and disconnected from the single limb circuit.

Press Standby to open the Standby window




V60 Plus and AC611 – HFT to NIV

Select Ventilation

Previous NIV Setting

O2 remains consistent
from HFT to NIV




V60 Plus and AC611 – HFT to NIV




Replace the high flow interface with a Philips approved NIV Mask.

Review patient settings and alarms.
Place interface on your patient



V60 Plus and AC611 – HFT to NIV



How to transition from NIV to HFT on the V60 Plus

1. Simply remove the NIV mask from your patient and select the Standby tab
2. Then select HFT and ensure the AC611 hfnc with insertion sleeve completely blocks the FEP.
3. Confirm high flow setting, 10-80 LPM and oxygen concentration, 21% - 100% then Start HFT.
4. Place the AC611 hfnc on the patient and your patient is now receiving high flow therapy on your V60 Plus.



Philips V60 Plus and AC611

Facilitates rapid switching between NIV and HFT

Designed for efficient patient weaning


Enables quick escalation and intervention for optimal patient care

Allows more space at the bedside for timely patient care



Resources

Clinical Pathway



Evidence-based practice for noninvasive ventilation and high flow nasal cannula a summary of the literature

Thomas Piraino, RRT, FCSRT

Topics included

- COPD exacerbation
- Community-acquired pneumonia
- Immunocompromised patients
- Hypoxemic respiratory failure
- Cardiogenic pulmonary edema
- Post-extubation (immediate)
- Postoperative patients


Topics excluded

- Extubation failure
- Do not intubate/retreat
- Acute asthma
- Pre-intubation oxygenation

Executive summary of the current landscape

Noninvasive clinical scenario	NIV	HFNC
COPD exacerbation (pH 7.25–7.35)	Highly recommended	Recommended
Community-acquired pneumonia	Mixed evidence	Recommended
Immunocompromised patients	Recommended	Recommended
Hypoxemic respiratory failure PaO ₂ /FiO ₂ 200–300	Recommended	Recommended
PaO ₂ /FiO ₂ < 200	High risk	Recommended
Cardiogenic pulmonary edema	Highly recommended	Recommended
Post-extubation for high-risk patients (immediately post)	Recommended	Recommended
Post-extubation with COPD (early liberation)	Recommended	Recommended
Postoperative patients	Recommended	Inferior

* Mixed evidence exists in this category, without a clear consensus in the literature. Monitor patients closely and consider the possibility of escalation to invasive ventilation.
Recommendations based on the author's review of the currently available literature, including existing guidelines.



Reference: Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure. Eur Respir J 2017;50:1602426. <https://doi.org/10.1183/13993003.02426-2016>.

Providing evidence-based care to patients in need of respiratory support

Thomas Piraino, RRT, FCSRT

Noninvasive ventilation (NIV) in the form of bi-level positive airway pressure (BiPAP) or continuous positive airway pressure (CPAP) has long been a first-line therapy option for many acute respiratory failure.¹ The goals of NIV are to minimize the respiratory effort of the patient in respiratory failure, with the physiologic aim of improving ventilation and oxygenation.

High flow nasal cannula (HFNC) therapy has been used for patients for a number of years, but has gained popularity after the Clinical Effectiveness of Non-invasive Ventilation and Nasal Oxygen Therapy in Resuscitation with Acute Lung Injury (FLORALI) study published in 2015 in the New England Journal of Medicine. In the FLORALI trial, HFNC resulted in lower intubation rates and mortality in patients with acute respiratory failure with PaO₂/FiO₂ < 200 when compared to conventional oxygen therapy (COT) and NIV. Recently, there has been a significant amount of research published on the use of HFNC for a wide range of respiratory conditions.^{3–5}

This presentation will provide an overview of the current evidence for NIV and discuss the potential role for HFNC on the available data where HFNC is compared to NIV.

Thomas Piraino, RRT, FCSRT

Thomas Piraino is the Clinical Specialist, Mechanical Ventilation for the Centre of Excellence in Mechanical Ventilation at St. Michael's Hospital in Toronto, Ontario, and Lecturer (Adjunct) for the Department of Anesthesia, Division of Critical Care, McMaster University, Hamilton, Ontario.

He has spoken internationally at various respiratory and critical care conferences, and has published research and authored textbook chapters on the subjects of invasive and noninvasive mechanical ventilation and monitoring in the critical care environment.

He is also a member of the editorial boards of the Respiratory Care Journal and the Canadian Journal of Respiratory Therapy.

